吡格列酮、二甲双胍联用治疗新诊断2型糖尿病的疗效评估

Therapeutical Evaluation of the Combination of Pioglitazone and Metformin in Treating Patients with Newly Diagnosed Type 2 Diabetes Mellitus

目的:评估吡格列酮、二甲双胍联合应用治疗新诊断2型糖尿病的临床效果。方法:选择2016年9月至2017年2月我院收治的40例初诊为2型糖尿病患者作为研究对象,随机分成对照组与观察组,每组各20例,对照组单用二甲双胍治疗,观察组在对照组治疗基础上加用盐酸吡格列酮,经过3个月治疗以后,对比评估两组患者的临床治疗效果。结果:治疗后两组患者的FPG、HbAlc、FINS、HOMA-IR及TC、TG、LDL-C均较治疗前下降、HDL-C升高(P<0.05);治疗后观察组患者的FPG、HbAlc、FINS、HOMA-IR及TC、TG、LDL-C较对照组明显降低、HDL-C明显升高(P<0.05)。疗效方面,观察组总体有效率显著高于对照组(P<0.05)。结论:吡格列酮、二甲双胍联用能明显改善2型糖尿病患者糖脂代谢及胰岛素抵抗,且疗效优于单用二甲双胍。

Objective： In order to evaluate the clinical effects of the treatment of combination of pioglitazone and metformin in first-visit patients with diagnosed type 2 diabetes mellitus. Methods： 40 patients with newly diagnosed type 2 diabetes mellitus in our hospital from September 2016 to February 2017 were included and were randomly divided into the control group and the treatment group with 20 cases in each group. While in the control group,metformin was given and in the treatment group,the combination of metformin and pioglitazone was given for 3 months. Results： FPG,HbAlc,FINS,HOMA-IR,TC,TG,LDL-C were all decreased after treatment in the two groups（ P〈0. 05）,while HDL-C was increased（ P〈0. 05）. While FPG,HbAlc,FINS,HOMA-IR,TC,TG,LDL-C in the treatment group were significantly decreased after treatment than that in the control group（ P〈0. 05）,HDL-C was significantly increased（ P〈0. 05）. Compared to the therapeutic effect of the control group and the treatment group,the treatment group was significantly higher（ P〈0. 05）. Conclusion： Pioglitazone combined with metformin can significantly improve glucose,lipid metabolism and insulin resistance in type 2 diabetes patients,and the effect is better than metformin alone medication.